Yuandong Biotech announced that the Phase I/II clinical trial of the chemical class 1 innovative drug HP-002 tablets independently developed by Shanghai Chaoyang Pharmaceutical, a holding subsidiary of the company, to treat recurrent or difficult B-cell non-Hodgkin lymphoma has recently completed the first case of enrolling the test subjects. The drug was approved for clinical trials by the State Drug Administration on May 29, 2026, and the first case was enrolled in the Phase I dose escalation phase initiated this time.

Yuandong Biotech announced that the Phase I/II clinical trial of the chemical class 1 innovative drug HP-002 tablets independently developed by Shanghai Chaoyang Pharmaceutical, a holding subsidiary of the company, to treat recurrent or difficult B-cell non-Hodgkin lymphoma has recently completed the first case of enrolling the test subjects. The drug was approved for clinical trials by the State Drug Administration on May 29, 2026, and the first case was enrolled in the Phase I dose escalation phase initiated this time.